Hims & Hers Growth Story Has A Lot To Prove In 2026 [Seeking Alpha]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Seeking Alpha
Sequential revenue deceleration, margin contraction, and lowered FY25 guidance have pressured HIMS stock, but management maintains ambitious 2030 targets. New growth vectors—testosterone, menopause, Labs, and international expansion—are promising, yet have not driven meaningful revenue acceleration. Valuation offers 185% potential upside if HIMS delivers on their FY30 revenue and adjusted EBITDA targets, but execution risk remains high. Given the risk-reward, I continue to maintain a cautious 'buy' rating on the stock with a small position, as I allow management to prove its growth story in 2026. Looking for a portfolio of ideas like this one? Members of The REIT Forum get exclusive access to our subscriber-only portfolios. Learn More » matdesign24/iStock via Getty Images Introduction & Investment Thesis When I last wrote about Hims & Hers Health ( HIMS ), I upgraded the stock to a “buy.” At the time, the company had just launched its Menopause and Perimenopause special
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers And HIMZ: Short-Term Pain From Novo, Long-Term Opportunity Still Bright [Seeking Alpha]Seeking Alpha
- BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS) [Yahoo! Finance]Yahoo! Finance
- Hims & Hers: Growth Catalysts Or Margin Trap [Seeking Alpha]Seeking Alpha
- Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health (NYSE:HIMS) is now covered by analysts at Evercore ISI. They set an "in-line" rating and a $33.00 price target on the stock.MarketBeat
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 1/7/26 - Form 4
- 12/23/25 - Form 4
- 12/22/25 - Form 144
- HIMS's page on the SEC website